Pneumothorax

Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Workload, Breast cancer, Area, Odense University Hospital, Algorithm, Woman, Radiology, Pneumothorax, Artificial intelligence, AI, Research, Triage, Pathology, Deep learning, Use, AUC, Workflow, King's College London, NHS, ACV, ECR, Mammography, Radboud University Medical Center, Report, Patient, Poster, Human, Medical device

SEOUL, South Korea, Feb. 28, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the European Congress of Radiology (ECR) 2024, to be held in Vienna, Austria, from February 28 to March 3. Four will be presented through oral presentations and three as E-posters.

Key Points: 
  • Four out of seven AI products, including Lunit INSIGHT CXR, showed superior performance compared to human readers.
  • Lunit invites booth visitors at ECR 2024 to explore detailed information on the project and discuss potential future collaborations.
  • "We are proud to present our latest research findings at this year's ECR, demonstrating the robust performance and versatility of our Lunit INSIGHT suite in various clinical settings and scenarios.
  • Join Lunit at booth AI-15 in the EXPO X1 hall to witness how the Lunit INSIGHT suite is shaping the future of radiology across the globe.

Kakao Brain Unveils Labeler Project Exclusively for Medical Image preliminary report

Retrieved on: 
Tuesday, February 27, 2024
Persea schiedeana, Pneumothorax, AI, Brain, Quality of life, ArXiv, Pulmonary edema, Data, Label printer applicator, GitHub, Honey bee, Fracture, Research, Medical imaging

SEOUL, South Korea, Feb. 27, 2024 /PRNewswire/ -- On the 16th, Kakao Brain released a medical image labeler project on GitHub, capable of diagnosing specific diseases from chest X-ray image draft readings.

Key Points: 
  • SEOUL, South Korea, Feb. 27, 2024 /PRNewswire/ -- On the 16th, Kakao Brain released a medical image labeler project on GitHub, capable of diagnosing specific diseases from chest X-ray image draft readings.
  • Aiming to contribute to the improvement of medical diagnoses, Kakao Brain initiated research on a labeler project that extracts specific disease names more accurately and efficiently than models previously released by other companies.
  • Kakao Brain unveiled the Labeler project on GitHub and published a paper titled 'CheX-GPT: Harnessing Large Language Models for Enhanced Chest X-ray Report Labeling' on arXiv, an open-access archive.
  • Kim Il-du, CEO of Kakao Brain, stated, "We plan to release a test set we created so that many researchers can use Kakao Brain's Labeler project as a benchmark for testing."

Samsung Introduces Lunit AI Solutions for Enhanced Chest Screenings

Retrieved on: 
Thursday, January 25, 2024
Mobile, Wireless, Technology, Medical Devices, Health Technology, Software, Audio, Video, Biotechnology, Health, Oncology, Artificial Intelligence, Digital radiography, Artificial intelligence, Pleural effusion, Calcification, Patient, X-ray, Fibrosis, Pneumoperitoneum, Multimedia, Tuberculosis, Radiology, Radiography, AI, Samsung, Triage, Investment, Vision, Pneumothorax, FDA, Computer-aided, Therapy, Human, Atelectasis, Cardiomegaly, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240125366766/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240125366766/en/
    GM85 and GC85A Vision digital radiology devices will now be equipped with AI-powered software for chest screenings (Photo: Business Wire)
    The Lunit INSIGHT CXR, an AI-powered chest X-ray analysis solution, and Lunit Insight CXR Triage, an FDA 510(k)-cleared AI triage solution for critical chest findings, will enable Samsung’s CAD (Computer Aided Detection) AI to help radiologists manage the unprecedented volume of patient exams by prioritizing those with suspected abnormalities.
  • By partnering with Lunit, our Samsung digital radiology products will now have computer-assisted triage and notification software that analyzes adult chest X-ray images for the presence of suspected pleural effusion or pneumothorax.
  • “With innovation as its cornerstone, Samsung continues to drive solutions to provide excellent patient experiences, simplify technologist workflows and aid in faster diagnosis.
  • Samsung will offer the upgraded systems to North America and European markets and to the Middle East, South America and Southeast Asia.

Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening

Retrieved on: 
Tuesday, January 16, 2024
Pleural effusion, PACS, ERS, Pneumonia, Partnership, System, AI, Lung cancer, Samsung, Triage, Software, Electronics, Samsung Electronics, Intensive care medicine, Pneumothorax, FDA, Therapy, Image, Intensive care unit, Medical imaging

The collaboration centers around the integration of Lunit's AI technology into Samsung's premium X-ray devices, elevating the accuracy and speed of chest screening.

Key Points: 
  • The collaboration centers around the integration of Lunit's AI technology into Samsung's premium X-ray devices, elevating the accuracy and speed of chest screening.
  • Under the terms of the contract, Lunit will supply Samsung Electronics with two AI-powered chest screening solutions: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage.
  • The initial phase of this collaboration will see the X-ray devices, enhanced with Lunit's AI solutions, targeting the markets in the US, Canada, and Europe.
  • Lunit INSIGHT CXR Triage is an FDA-cleared AI solution that identifies pre-specified critical findings, such as pleural effusion or pneumothorax, on frontal chest X-ray images.

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

Retrieved on: 
Tuesday, November 28, 2023
Software, Research, Radiology, Data Management, Technology, Medical Devices, Hospitals, Artificial Intelligence, Science, Biotechnology, FDA, Health, Other Science, Nurse practitioner, AMX, Physician, ICU, Google Images, UCSF, Multimedia, GE HealthCare, PTX, Intelligence, Diagnosis, AI, Triage, Critical care, DICOM, Medical imaging, PACS, Pneumothorax

Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX.

Key Points: 
  • Today GE HealthCare (Nasdaq: GEHC) announced an industry-first US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax (PTX) algorithm for the detection, notification, triage and diagnosis of PTX.
  • View the full release here: https://www.businesswire.com/news/home/20231128224829/en/
    On-device, CCS2.1 output from GE HealthCare's AMX Navigate mobile X-ray system showing PTX overlay and confidence level.
  • With this latest update, Critical Care Suite 2.1 provides immediate on-device detection and triage notifications for the presence or absence of pneumothorax (PTX).
  • By hosting Critical Care Suite on-device, critical insights are available at the point of care and across the entire clinical care team.

Bering Secures FDA Clearance for AI-Based Chest X-Ray Triage Solution

Retrieved on: 
Wednesday, December 6, 2023
Research, Pneumothorax, Food, Patient safety, US Foods, CXR, Algorithm, FDA, Food and Drug Administration, AI, Pleural effusion, Triage, Medical device, Medical imaging, ROC

FDA 510(k) clearance for AI Radiology software product, targeting emergency cases found on chest X-Rays.

Key Points: 
  • FDA 510(k) clearance for AI Radiology software product, targeting emergency cases found on chest X-Rays.
  • Bering to accelerate business in the US market, leveraging new and existing partnerships
    LONDON, Dec. 6, 2023 /PRNewswire/ -- Bering Limited, a London-based medical AI company, today announced it received US Food and Drug Administration (FDA) 510(k) clearance for its AI-powered chest X-Ray triage solution, 'BraveCX'.
  • With the FDA clearance, the company is now able to commercially provide the AI solution to medical professionals and healthcare institutions in the US.
  • FDA clearance means BraveCX prioritises patient safety, whilst still delivering the most advanced Risk Stratification algorithms where they are needed the most."

ConcertAI's TeraRecon, Integrates Clinical and Generative AI, Supporting Clinical Research and Advancing Clinical Care Solutions at #RSNA23

Retrieved on: 
Monday, November 20, 2023
Dark, CT scan, RSNA, Generative, Gen, Research, Real, Catalog, Pneumothorax, Human, The Advanced Visualizer, Synthetic media, Collection, Cardiology, Physician, PACS, Scientist, Hospital, Patient, Education minister, Data analysis, Multi, Algorithm, Lurie Children's Hospital, Q&A, Trial of the century, Diagnosis, Doctor of Philosophy, Health care, AI, MSKCC, Health, Medical imaging, Medical device, Nightclub

CAMBRIDGE, Mass., Nov. 20, 2023 /PRNewswire/ -- ConcertAI's TeraRecon, the advanced visualization and clinical AI leader, recently unveiled first-in-category capabilities in advanced visualization, AI, and expansions to its AI partner ecosystem to enhance research capabilities and support complex clinical study workflows. These solutions will provide researchers with enhanced data analysis tools for in-depth study, contributing to more informed care strategies that can improve patient outcomes.

Key Points: 
  • New solutions empower clinicians and research teams with AI orchestration, model development, visualization, and multi-modal data management to power clinical research, clinical trials, and patient care strategies.
  • These solutions will provide researchers with enhanced data analysis tools for in-depth study, contributing to more informed care strategies that can improve patient outcomes.
  • Leveraging ConcertAI's Eureka Life Science AI Platform, powered by TeraRecon, MSKCC will drive advancements in multi-modal AI workflows, using clinical and radiological imaging data.
  • Our joint vision is clear: advance the utility and efficacy of Clinical AI in oncology research, extending its benefits to more patients and institutions in the future.

ConcertAI's TeraRecon Partners with GLEAMER to Advance Clinical AI Capabilities on the Eureka Clinical AI Platform

Retrieved on: 
Monday, August 14, 2023
CE, Partnership, Pneumothorax, Radiology, Pleural effusion, Patient, Fracture, Algorithm, AI, Cardiology, Elective surgery, FDA, Neurology, Medical device, Medical imaging

CAMBRIDGE, Mass., Aug. 14, 2023 /PRNewswire/ -- Advanced visualization and AI leader TeraRecon, a ConcertAI company, is proud to announce its strategic partnership with GLEAMER, a leading provider of AI solutions for medical imaging. By joining forces, the two companies aim to advance the field of radiology by integrating GLEAMER's BoneView and ChestView solutions into TeraRecon's Eureka Clinical AI Platform.

Key Points: 
  • By joining forces, the two companies aim to advance the field of radiology by integrating GLEAMER's BoneView and ChestView solutions into TeraRecon's Eureka Clinical AI Platform.
  • GLEAMER's BoneView (FDA) and BoneView (CE), which offer AI-powered bone fracture identification, will seamlessly integrate with the Eureka Clinical AI platform.
  • "We are thrilled to partner with GLEAMER and integrate their advanced AI algorithms into the Eureka Clinical AI platform," said Dan McSweeney, President of TeraRecon.
  • Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: https://www.terarecon.com/artificial-intelligence

Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc.

Retrieved on: 
Thursday, June 8, 2023
Jointer, Hospital, Dilute Russell's viper venom time, Thrombus, Pneumothorax, GAAP, MMSI, Dialysis, Incidence, Dialysis catheter, Acquisition, Patient, EPS, Bank, Medical device

Merit also announced the recent acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc. for a total cash consideration of $32.5 million.

Key Points: 
  • Merit also announced the recent acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc. for a total cash consideration of $32.5 million.
  • “These acquisitions strengthen our position in the dialysis and biopsy markets, and expand the foundation of our growing specialty dialysis device offering, which includes WRAPSODY™ Cell-Impermeable Endoprosthesis, HeRO® Graft, and the Surfacer System devices.
  • In addition to the dialysis portfolio, Merit also acquired the BioSentry® Biopsy Tract Sealant System from AngioDynamics, which complements Merit’s comprehensive biopsy portfolio.
  • Merit is reaffirming prior full-year 2023 financial guidance ranges for the stand-alone Merit business previously announced on April 26, 2023.

Iraqi Patient Successfully Undergoes Robotic-Assisted CABG Surgery at Manipal Hospital, Delhi

Retrieved on: 
Wednesday, May 24, 2023
Infection, Pneumothorax, CABG, Male, Rabindranath Tagore International Institute of Cardiac Sciences, Diagnosis, Cancer, OLV, Scar, Manipal Hospitals, Chest pain, Bleeding, Patient, Risk, Dentistry

NEW DELHI, May 24, 2023 /PRNewswire/ -- Doctors at Manipal Hospital, Delhi recently performed a groundbreaking robotic-assisted Coronary Artery Bypass Grafting (CABG) surgery on a 44-year-old male patient from Iraq.

Key Points: 
  • NEW DELHI, May 24, 2023 /PRNewswire/ -- Doctors at Manipal Hospital, Delhi recently performed a groundbreaking robotic-assisted Coronary Artery Bypass Grafting (CABG) surgery on a 44-year-old male patient from Iraq.
  • As the patient was already undergoing cancer treatment, looking at his condition Dr. Yugal Kishore Mishra, Chief of Clinical Services, Head of Cardiac Sciences, and Chief Cardiovascular Surgeon at Manipal Hospital, Delhi and his team decided to proceed with robotic-assisted CABG surgery.
  • Unlike traditional CABG surgery, robotic-assisted CABG enables patients to experience a faster recovery time, minimal scarring, and potentially improved graft placement, thanks to its minimally invasive technique.
  • Robotic-assisted CABG offers several advantages over traditional CABG surgery, including smaller incisions, greater precision, reduced blood loss, shorter hospital stays, and faster return to daily activities.